Discover a study on psoriasis treatment failure, highlighting when to move from topical therapies to systemic care for ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque ...
Treatment with GLP-1 RAs was linked to decreased risks for all-cause mortality and MACE in patients with psoriasis when compared with other antidiabetic or obesity drugs.
Adhering to a Mediterranean diet significantly improved disease severity among patients with psoriasis, independent of weight ...
News-Medical.Net on MSN
Innovative vibroacoustic sensor could revolutionize eczema and psoriasis treatment
A groundbreaking technology developed by Heriot-Watt University has received over £475,000 in funding to revolutionize how ...
Anti-IL-17A biologics have the greatest odds of achieving and maintaining clear or almost clear skin among patients with psoriasis.
Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® ...
MedPage Today on MSN
'Hit Hard, Hit Early' Psoriasis Treatment Strategy Gains Momentum
The advantage of earlier treatment was evident in patients who achieved so-called "super-responder" status and those who did ...
Treatment with the IL-23 inhibitor significantly improved skin clearance in the pediatric study of children aged 6-17 with ...
Psoriasis may not have a cure, but new research has found that significant relief could be achieved at the dinner table. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback